An Investigation of the Steady-State Pharmacokinetics of Oral Valacyclovir in Immunocompromised Children

Nadal, David; Leverger, Guy; Sokal, Etienne M.; Floret, Daniel; Perel, Yves; Leibundgut, Kurt; Weller, Stephen (2002). An Investigation of the Steady-State Pharmacokinetics of Oral Valacyclovir in Immunocompromised Children. Journal of infectious diseases, 186(Suppl 1), S123-S130. The University of Chicago Press 10.1086/342968

Preview

Text 186-Supplement_1-S123.pdf - Published Version Available under License Publisher holds Copyright. Download (123kB) | Preview

Valacyclovir was administered to 28 immunocompromised children (ages 5–12 years) to obtain preliminary pharmacokinetic and safety information. Patients were randomized to valacyclovir regimens of 250 mg (9.4–13.3 mg/kg) or 500 mg (13.9–27.0 mg/kg) twice daily or 500 mg (13.2–21.7 mg/kg) 3 times a day. Acyclovir pharmacokinetics were evaluated at steady state. Valacyclovir was rapidly absorbed and converted to acyclovir. Mean (±SD) acyclovir peak concentrations from 250 mg and 500 mg valacyclovir were 4.11±1.41 and 5.19±1.96 μg/mL, respectively. Corresponding single dose area-under-curve values were 12.14±6.60 and 14.49±4.69h×μg/mL. By using historical data for intravenous acyclovir as reference, the overall estimate of acyclovir bioavailability from valacyclovir was 48%, 2- to 4-fold greater than for oral acyclovir. In general, adverse events were not attributable to valacyclovir and were consistent with disease-related expectations and concomitant therapies. Dosage options for using valacyclovir in children are discussed.

Interest & Impact

Downloads

122 since deposited on 08 Oct 2020
24 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item